{
    "id": 22891,
    "fullName": "NRG1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NRG1 positive indicates the presence of the NRG1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3084,
        "geneSymbol": "NRG1",
        "terms": [
            "NRG1",
            "ARIA",
            "GGF",
            "GGF2",
            "HGL",
            "HRG",
            "HRG1",
            "HRGA",
            "MST131",
            "MSTP131",
            "NDF",
            "NRG1-IT2",
            "SMDF"
        ]
    },
    "variant": "positive",
    "createDate": "05/19/2016",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11407,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 9F7-F11 inhibited tumor growth and improved survival in a lung cancer cell line xenograft model expressing low levels of NRG1 (PMID: 28507002).",
            "molecularProfile": {
                "id": 23513,
                "profileName": "NRG1 positive"
            },
            "therapy": {
                "id": 5976,
                "therapyName": "9F7-F11",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9293,
                    "pubMedId": 28507002,
                    "title": "Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28507002"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11405,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 9F7-F11 decreased viability of pancreatic cancer cell lines in the presence of NRG1 in culture, and inhibited tumor growth and improved survival in an NRG1-expressing pancreatic cancer cell line xenograft model (PMID: 28507002).",
            "molecularProfile": {
                "id": 23513,
                "profileName": "NRG1 positive"
            },
            "therapy": {
                "id": 5976,
                "therapyName": "9F7-F11",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9293,
                    "pubMedId": 28507002,
                    "title": "Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28507002"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11406,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, 9F7-F11 inhibited tumor growth and improved survival in an NRG1-expressing triple-negative breast cancer cell line xenograft model (PMID: 28507002).",
            "molecularProfile": {
                "id": 23513,
                "profileName": "NRG1 positive"
            },
            "therapy": {
                "id": 5976,
                "therapyName": "9F7-F11",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9293,
                    "pubMedId": 28507002,
                    "title": "Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28507002"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11935,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cell lines with elevated expression of ERBB3 (HER3) and NRG1 were sensitive to treatment with Tykerb (lapatinib) in culture (PMID: 21840482).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9923,
                    "pubMedId": 21840482,
                    "title": "Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21840482"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6461,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Erbitux (cetuximab) and CDX-3379 (KTN3379) synergized to inhibit tumor growth in human cell line xenograft models of gastric cancer expressing Erbb3 (Her3) and Nrg1 (Hrg) (PMID: 26880266).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 2061,
                "therapyName": "CDX-3379 + Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6454,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of head and neck squamous cell carcinoma expressing Erbb3 (Her3) and Nrg1 (Hrg) (PMID: 26880266).",
            "molecularProfile": {
                "id": 23514,
                "profileName": "ERBB3 pos NRG1 pos"
            },
            "therapy": {
                "id": 2054,
                "therapyName": "CDX-3379",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5601,
                    "pubMedId": 26880266,
                    "title": "A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26880266"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23513,
            "profileName": "NRG1 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23514,
            "profileName": "ERBB3 pos NRG1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}